Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prucalopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prucalopride SCHEMBL7970517 | 0.99 | HTR4 (0.98) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL1230671 | 0.99 | HTR4 (0.98) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL28260565 | 0.99 | HTR4 (0.98) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7960440 | 0.99 | HTR4 (0.98) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7426504 | 0.97 | HTR4 (0.95) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7972121 | 0.97 | HTR4 (0.95) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL27531479 | 0.97 | HTR4 (0.93) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7972080 | 0.97 | HTR4 (0.93) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL7971609 | 0.97 | HTR4 (0.93) | HTR4HTR1AADRA2CACHEPTGS1 | |
| Prucalopride SCHEMBL1230437 | 0.96 | HTR4 (0.92) | HTR4HTR1AADRA2CACHEPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2977 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | claimed |
| EP-4633614-A1 | STABLE PHARMACEUTICAL COMPOSITION OF AN AMINE DRUG | Sun Pharmaceutical Industries Limited (IN) | 2025-10-22 | — | — | EP | claimed |
| US-20250213564-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. | 2025-07-03 | — | — | US | claimed |
| EP-4577305-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | 1/1THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-02 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250170170-A1 | BOWEL-CLEANSING COMPOSITION | DAEWOONG THERAPEUTICS INC. (KR) | 2025-05-29 | — | — | US | claimed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | claimed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | claimed |
| WO-2025037323-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DRY EYE DISEASE AND ASSOCIATED DISORDERS | KOTHAPUVARI PAVAN KUMAR (IN) | 2025-02-20 | — | — | WO | claimed |
| CN-114539133-B | Method for preparing prucalopride intermediate 1- (3-methoxypropyl) -4-piperidinamine | 鲁南制药集团股份有限公司 | 2024-09-20 | — | — | CN | claimed |
| WO-2001095902-A9 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | — | 2002-04-25 | — | — | WO | claimed |
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | claimed |
| EP-1173168-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | Respiratorius AB (SE) | 2002-01-23 | — | — | EP | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| EP-1135130-A1 | USE OF PRUCALOPRIDE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DYSPEPSIA | Janssen Pharmaceutica N.V. (BE) | 2001-09-26 | — | — | EP | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | claimed |
| WO-2000030640-A1 | USE OF PRUCALOPRIDE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DYSPEPSIA | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-02 | — | — | WO | claimed |
| EP-0807110-A1 | ENTEROKINETIC BENZAMIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-11-19 | — | — | EP | claimed |
| WO-1996016060-A1 | ENTEROKINETIC BENZAMIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-05-30 | — | — | WO | claimed |